Gastric protein is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
=== Refresh frequency limits for common resolutions === The maximum limits for the RBR and HBR modes are calculated using standard data rate calculations. For UHBR modes, the limits are based on the data efficiency calculations provided by the DisplayPort standard. All calculations assume uncompressed RGB video with CVT-RB v2 timing. Maximum limits may differ if compression (i.e. DSC) or Y′CBCR 4:2:2 or 4:2:0 chroma subsampling are used. Display manufacturers may also use non-standard blanking intervals rather than CVT-RB v2 to achieve even higher frequencies when bandwidth is a constraint. The refresh frequencies in the below table do not represent the absolute maximum limit of each interface, but rather an estimate based on a modern standardized timing formula. The minimum blanking intervals (and therefore the exact maximum frequency that can be achieved) will depend on the display and how many secondary data packets it requires, and therefore will differ from model to model.
==== Liothyronine ==== Treatment with liothyronine (synthetic T3) alone has not received enough study to make a recommendation as to its use; due to its shorter half-life it would need to be taken more often than levothyroxine. Adding liothyronine to levothyroxine has been suggested as a measure to provide better symptom control, but this has not been confirmed by studies. In 2007, the British Thyroid Association stated that combined T4 and T3 therapy carried a higher rate of side effects and no benefit over T4 alone. Similarly, American guidelines discourage combination therapy due to a lack of evidence, although they acknowledge that some people feel better when receiving combination therapy. Guidelines by National Institute for Health and Care Excellence (NICE) discourage liothyronine. People with hypothyroidism who do not feel well despite optimal levothyroxine dosing may request adjunctive treatment with liothyronine. A 2012 guideline from the European Thyroid Association recommends that support should be offered concerning the chronic nature of the disease and that other causes of the symptoms should be excluded. The addition of liothyronine should be regarded as experimental, initially only for a trial period of 3 months, and in a set ratio to the current dose of levothyroxine. The guideline explicitly aims to enhance the safety of this approach and to counter its indiscriminate use. A 2014 guideline from the American Thyroid Association recommends against the use of liothyronine.
Predator-prey interactions between biofilms and bacterivores, such as the soil-dwelling nematode Caenorhabditis elegans, had been extensively studied. Via the production of sticky matrix and formation of aggregates, Yersinia pestis biofilms can prevent feeding by obstructing the mouth of C. elegans. Moreover, Pseudomonas aeruginosa biofilms can impede the slithering motility of C. elegans, termed as 'quagmire phenotype', resulting in trapping of C. elegans within the biofilms and preventing the exploration of nematodes to feed on susceptible biofilms. This significantly reduced the ability of predator to feed and reproduce, thereby promoting the survival of biofilms. Capsular exopolysaccharides can protect pathogenic bacteria against desiccation and predation, and contribute to their pathogenicity. Sessile bacteria fixed and aggregated in biofilms are less vulnerable compared to drifting planktonic bacteria, as the EPS matrix is able to act as a protective diffusion barrier. The physical and chemical characteristics of bacterial cells can be affected by EPS composition, influencing factors such as cellular recognition, aggregation, and adhesion in their natural environments.
== Plot == At the underground Black Mesa Research Facility, the theoretical physicist Gordon Freeman participates in an experiment on a crystal of unknown origin. This triggers a "resonance cascade", which greatly damages the facility and teleports in hostile alien creatures. Eli Vance tells Freeman to get to the surface and find help. After going through several layers of Black Mesa, Freeman discovers that United States Marines and black operators have been dispatched to the facility to terminate the aliens but also to cover up the incident by eliminating all the remaining Black Mesa personnel. A scientist instructs him to make his way to the Lambda Complex to stop the alien invasion. Freeman then discovers a monster called the Tentacle, and kills the giant creature using a rocket engine test facility that incinerates it, and uses an underground monorail to reach a rocket silo. He launches a satellite to help the Lambda team, but is captured by vengeful Marines and left for dead in a trash compactor. Escaping through a waste treatment complex, Freeman travels through a part of Black Mesa filled with alien specimens, collected long before the resonance cascade. Overpowered by the aliens, the Marines withdraw and begin to launch air strikes. Freeman crosses the facility's surface to reach the Lambda Complex, where he discovers secret teleportation technology. There, scientists inform him that a powerful alien creature is preventing them from closing the portal. They teleport him to the alien dimension Xen to kill it.
Sources: en.wikipedia.org
The studies and plans for the TTC's proposed "desperately needed extension known as the Relief Line", had begun in the late 2010s. By early 2019, the planning for the Relief Line was "well underway and construction was scheduled to begin in 2020, with projected completion in 2029." In April 2019, Ford put the Relief Line project on hold in favour of the Ontario Line, which would use a different route with significant lengths of at-grade or elevated track. On September 25, 2024, Ford promised to build a traffic tunnel under the Highway 401 to relieve congestion, and campaigned on constructing the Bradford Bypass. On October 21, 2024, Ford tabled a bill, titled the Reducing Gridlock, Saving You Time Act, granting the province authority to remove bike lanes from several arterial roads in Toronto, as well as expedite the construction of Highway 413. The bill would also require municipalities to get provincial approval before replacing any automotive lanes with bike lanes. Toronto City Council formally opposed the plan, citing an estimated cost of $48 million to remove the bike lanes on Bloor, Avenue, and Yonge. On November 21, Ford's government made several amendments to the bill which the opposition claimed would protect the province from liability if a cyclist were injured or killed due to the removal of the lanes. The bill passed on November 25, 2024. Ford's bill has faced opposition from local politicians and cycling advocates on grounds of provincial overreach and potential safety impacts to cyclists.
== Exam preparation == AAB developed a two-day review program to help individuals prepare for the HEW Proficiency Examination, known as the “Proficiency Examination Reviews” or “PERs”. The notes used during the reviews were compiled into a reference manual that became the PER Handbook which continued into its tenth edition in 2016.
== See also == Analysis, the converse of synthesis Carlson curve Synthesizer (disambiguation) Synthetic (disambiguation) Creation (disambiguation) Formation (disambiguation) Production (disambiguation) Derivation (disambiguation)
Sources: en.wikipedia.org
==== Mollusks ==== In cephalopods, the models used for the studies of cartilage are Octopus vulgaris and Sepia officinalis. The cephalopod cranial cartilage is the invertebrate cartilage that shows more resemblance to the vertebrate hyaline cartilage. The growth is thought to take place throughout the movement of cells from the periphery to the center. The chondrocytes present different morphologies related to their position in the tissue. The embryos of S. officinalis express ColAa, ColAb, and hyaluronan in the cranial cartilages and other regions of chondrogenesis. This implies that the cartilage is fibrillar-collagen-based. The S. officinalis embryo expresses hh, whose presence causes ColAa and ColAb expression and is also able to maintain proliferating cells undiferentiated. It has been observed that this species presents the expression SoxD and SoxE, analogs of the vertebrate Sox5/6 and Sox9, in the developing cartilage. The cartilage growth pattern is the same as in vertebrate cartilage. In gastropods, the interest lies in the odontophore, a cartilaginous structure that supports the radula. The most studied species regarding this particular tissue is Busycotypus canaliculatus. The odontophore is a vesicular cell rich cartilage, consisting of vacuolated cells containing myoglobin, surrounded by a low amount of extra cellular matrix containing collagen. The odontophore contains muscle cells along with the chondrocytes in the case of Lymnaea and other mollusks that graze vegetation.
=== Chalcogenides and pnictides === Sulfides, selenides and tellurides of curium have been obtained by treating curium with gaseous sulfur, selenium or tellurium in vacuum at elevated temperature. Curium pnictides of the type CmX are known for nitrogen, phosphorus, arsenic and antimony. They can be prepared by reacting either curium(III) hydride (CmH3) or metallic curium with these elements at elevated temperature.
=== Mechanism of Action === In humans, uric acid is the final step in the catabolic pathway of purines. Rasburicase catalyzes enzymatic oxidation of poorly soluble uric acid into an inactive and more soluble metabolite allantoin with carbon dioxide and hydrogen peroxide as byproducts in the chemical reaction.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.